-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, April 9th.
Recently, the National Medical Products Administration of China approved the listing application of Qingle (Repetinib) for the treatment of 3 or more kinase inhibitors including imatinib.
Of adult patients with advanced gastrointestinal stromal tumor (GIST).
This approval marks that Repetinib will become the first GIST fourth-line therapeutic drug approved to be marketed in Mainland China, filling the gap in the treatment of this disease in my country.
Recently, the National Medical Products Administration of China approved the listing application of Qingle (Repetinib) for the treatment of 3 or more kinase inhibitors including imatinib.
Of adult patients with advanced gastrointestinal stromal tumor (GIST).
This approval marks that Repetinib will become the first GIST fourth-line therapeutic drug approved to be marketed in Mainland China, filling the gap in the treatment of this disease in my country.
GIST is a mesenchymal tumor of the gastrointestinal tract.
The disease can occur in any part of the entire digestive tract.
The stomach and small intestine are the most common, accounting for 1% to 3% of gastrointestinal malignancies.
It is a rare tumor and occurs more frequently in people over 50 years of age.
The disease can occur in any part of the entire digestive tract.
The stomach and small intestine are the most common, accounting for 1% to 3% of gastrointestinal malignancies.
It is a rare tumor and occurs more frequently in people over 50 years of age.
At present, surgical resection is an important means for early treatment of GIST, but nearly 50% of patients with complete tumor resection still have recurrence or metastasis after surgery.
For these patients with unresectable, metastatic or recurring advanced GIST, molecular targeted therapy is the main clinical treatment, and the commonly used drugs include imatinib, sunitinib and regorafenib, which are the first and second lines of GIST, respectively And third-line treatments are unanimously recommended by domestic and foreign guidelines.
For these patients with unresectable, metastatic or recurring advanced GIST, molecular targeted therapy is the main clinical treatment, and the commonly used drugs include imatinib, sunitinib and regorafenib, which are the first and second lines of GIST, respectively And third-line treatments are unanimously recommended by domestic and foreign guidelines.
"But GIST is a complex disease , in some patients after receiving a second and third tier targeted drug therapy, still secondary to new genetic mutations that cause resistance to produce original drugs.
" Peking University Tumor Hospital vice president Lin Shen Emphasize that due to the lack of effective back-line drugs, patients have a huge unmet need for treatment.
Repetinib's approval for the market provides a new treatment plan for domestic GIST patients, and further helps patients improve their prognosis and improve their quality of life.
" Peking University Tumor Hospital vice president Lin Shen Emphasize that due to the lack of effective back-line drugs, patients have a huge unmet need for treatment.
Repetinib's approval for the market provides a new treatment plan for domestic GIST patients, and further helps patients improve their prognosis and improve their quality of life.
Medical Network, April 9th.
Recently, the National Medical Products Administration of China approved the listing application of Qingle (Repetinib) for the treatment of 3 or more kinase inhibitors including imatinib.
Of adult patients with advanced gastrointestinal stromal tumor (GIST).
This approval marks that Repetinib will become the first GIST fourth-line therapeutic drug approved to be marketed in Mainland China, filling the gap in the treatment of this disease in my country.
Recently, the National Medical Products Administration of China approved the listing application of Qingle (Repetinib) for the treatment of 3 or more kinase inhibitors including imatinib.
Of adult patients with advanced gastrointestinal stromal tumor (GIST).
This approval marks that Repetinib will become the first GIST fourth-line therapeutic drug approved to be marketed in Mainland China, filling the gap in the treatment of this disease in my country.
GIST is a mesenchymal tumor of the gastrointestinal tract.
The disease can occur in any part of the entire digestive tract.
The stomach and small intestine are the most common, accounting for 1% to 3% of gastrointestinal malignancies.
It is a rare tumor and occurs more frequently in people over 50 years of age.
The disease can occur in any part of the entire digestive tract.
The stomach and small intestine are the most common, accounting for 1% to 3% of gastrointestinal malignancies.
It is a rare tumor and occurs more frequently in people over 50 years of age.
At present, surgical resection is an important means for early treatment of GIST, but nearly 50% of patients with complete tumor resection still have recurrence or metastasis after surgery.
For these patients with unresectable, metastatic or recurring advanced GIST, molecular targeted therapy is the main clinical treatment, and the commonly used drugs include imatinib, sunitinib and regorafenib, which are the first and second lines of GIST, respectively And third-line treatments are unanimously recommended by domestic and foreign guidelines.
For these patients with unresectable, metastatic or recurring advanced GIST, molecular targeted therapy is the main clinical treatment, and the commonly used drugs include imatinib, sunitinib and regorafenib, which are the first and second lines of GIST, respectively And third-line treatments are unanimously recommended by domestic and foreign guidelines.
"But GIST is a complex disease , in some patients after receiving a second and third tier targeted drug therapy, still secondary to new genetic mutations that cause resistance to produce original drugs.
" Peking University Tumor Hospital vice president Lin Shen Emphasize that due to the lack of effective back-line drugs, patients have a huge unmet need for treatment.
Repetinib's approval for the market provides a new treatment plan for domestic GIST patients, and further helps patients improve their prognosis and improve their quality of life.
" Peking University Tumor Hospital vice president Lin Shen Emphasize that due to the lack of effective back-line drugs, patients have a huge unmet need for treatment.
Repetinib's approval for the market provides a new treatment plan for domestic GIST patients, and further helps patients improve their prognosis and improve their quality of life.
Medical Network, April 9th.
Recently, the National Medical Products Administration of China approved the listing application of Qingle (Repetinib) for the treatment of 3 or more kinase inhibitors including imatinib.
Of adult patients with advanced gastrointestinal stromal tumor (GIST).
This approval marks that Repetinib will become the first GIST fourth-line therapeutic drug approved to be marketed in Mainland China, filling the gap in the treatment of this disease in my country.
Recently, the National Medical Products Administration of China approved the listing application of Qingle (Repetinib) for the treatment of 3 or more kinase inhibitors including imatinib.
Of adult patients with advanced gastrointestinal stromal tumor (GIST).
This approval marks that Repetinib will become the first GIST fourth-line therapeutic drug approved to be marketed in Mainland China, filling the gap in the treatment of this disease in my country.
GIST is a mesenchymal tumor of the gastrointestinal tract.
The disease can occur in any part of the entire digestive tract.
The stomach and small intestine are the most common, accounting for 1% to 3% of gastrointestinal malignancies.
It is a rare tumor and occurs more frequently in people over 50 years of age.
The disease can occur in any part of the entire digestive tract.
The stomach and small intestine are the most common, accounting for 1% to 3% of gastrointestinal malignancies.
It is a rare tumor and occurs more frequently in people over 50 years of age.
At present, surgical resection is an important means for early treatment of GIST, but nearly 50% of patients with complete tumor resection still have recurrence or metastasis after surgery.
For these patients with unresectable, metastatic or recurring advanced GIST, molecular targeted therapy is the main clinical treatment, and the commonly used drugs include imatinib, sunitinib and regorafenib, which are the first and second lines of GIST, respectively And third-line treatments are unanimously recommended by domestic and foreign guidelines.
For these patients with unresectable, metastatic or recurring advanced GIST, molecular targeted therapy is the main clinical treatment, and the commonly used drugs include imatinib, sunitinib and regorafenib, which are the first and second lines of GIST, respectively And third-line treatments are unanimously recommended by domestic and foreign guidelines.
"But GIST is a complex disease , in some patients after receiving a second and third tier targeted drug therapy, still secondary to new genetic mutations that cause resistance to produce original drugs.
" Peking University Tumor Hospital vice president Lin Shen Emphasize that due to the lack of effective back-line drugs, patients have a huge unmet need for treatment.
Repetinib's approval for the market provides a new treatment plan for domestic GIST patients, and further helps patients improve their prognosis and improve their quality of life.
Disease Disease Disease Tumor Hospital Tumor Tumor Hospital Hospital " Peking University Tumor Hospital vice president Lin Shen Emphasize that due to the lack of effective back-line drugs, patients have a huge unmet need for treatment.
Repetinib's approval for the market provides a new treatment plan for domestic GIST patients, and further helps patients improve their prognosis and improve their quality of life.
